Why is the free thyroxine low in a patient taking levothyroxine 137 µg, with an elevated free triiodothyronine on liothyronine 50 µg and a suppressed thyroid‑stimulating hormone?

Understanding Low Free T4 on Combination Thyroid Therapy

The low free T4 of 0.66 in this patient on 137 mcg levothyroxine combined with 50 mcg liothyronine is expected and physiologically appropriate—the high-dose liothyronine (T3) is suppressing TSH, which reduces endogenous T4 production and peripheral T4-to-T3 conversion, while the T3 itself provides direct thyroid hormone action that maintains the relatively normal TSH of 0.570.

Why This Pattern Occurs

The Physiologic Mechanism

When patients take liothyronine (T3) in combination with levothyroxine (T4), several key changes occur:

• Direct T3 feedback: The exogenous T3 (liothyronine 50 mcg is a substantial dose) directly suppresses TSH at the pituitary level 1
• Reduced T4-to-T3 conversion: Lower TSH means less stimulation of deiodinase enzymes that normally convert T4 to T3
• Altered equilibrium: The normal interlocking relationship between TSH, free T4, and free T3 becomes disrupted when T3 is given directly 2

The Dose Context Matters

The 50 mcg liothyronine dose is quite high—this is approximately equivalent to 150-200 mcg of levothyroxine in terms of metabolic effect. Combined with 137 mcg levothyroxine, the total thyroid hormone load is substantial, which explains:

• Why TSH is in the lower-normal range (0.570)
• Why free T3 is elevated at 3.4
• Why free T4 appears "low"—it's being outcompeted by the direct T3 administration

What the Evidence Shows

Combination Therapy Alters Normal Ratios

In patients receiving levothyroxine monotherapy, free T4 levels tend to run higher than in untreated euthyroid individuals 3. However, when liothyronine is added:

• The free T3/free T4 ratio becomes markedly altered 4
• Patients on combination therapy show lower free T4 levels relative to their free T3 2
• TSH becomes an unreliable marker of adequate replacement when T3 is given directly 5

Measurement Timing Is Critical

Blood should be drawn before the morning dose of thyroid medication 5. Free T4 can increase by up to 20% within hours of levothyroxine administration, and this transient elevation can confound interpretation 5. If this patient's labs were drawn after taking medications, the free T4 might be even lower at true trough.

Clinical Assessment Algorithm

Step 1: Verify the Clinical Context

• Is the patient truly hypothyroid? Confirm original diagnosis with pre-treatment labs
• Why is the patient on combination therapy? Most guidelines do not recommend routine liothyronine use 5, 6
• Are there symptoms? The biochemical pattern matters less than clinical status

Step 2: Check for Interference

Evaluate for factors that reduce levothyroxine absorption 5:

• Timing: Is levothyroxine taken 30-60 minutes before breakfast on an empty stomach?
• Medications: Iron supplements (even with 4-hour separation can still interfere 7), calcium, proton pump inhibitors, bile acid sequestrants
• Gastrointestinal issues: Celiac disease, atrophic gastritis, inflammatory bowel disease
• Brand switching: Different levothyroxine formulations can affect absorption 8

Step 3: Assess Tissue Thyroid Status

Since TSH is unreliable in this scenario 5, 1:

• Free T3 level of 3.4: This is the biologically active hormone—if the reference range upper limit is around 4.0-4.5, this patient is well-repleted
• Clinical symptoms: Energy, weight, heart rate, cognition, mood
• Cardiovascular effects: The elderly and those with heart disease are at risk from overtreatment 9

The Key Question: Is This Harmful?

This Pattern Is Not Necessarily Problematic

The critical issue is whether tissue thyroid hormone action is adequate, not whether free T4 sits in a particular range 2, 4. In patients on combination therapy:

• Free T4 levels below the reference range can be acceptable if free T3 is adequate
• TSH in the 0.5-2.0 range suggests reasonable pituitary feedback
• The free T3/free T4 ratio is inherently abnormal with exogenous T3 administration

When to Worry

Reduce or discontinue liothyronine if:

• Free T3 is frankly elevated above the reference range (appears borderline here at 3.4)
• TSH is suppressed below 0.1-0.3 mIU/L (not the case here)
• Patient has cardiovascular symptoms: palpitations, atrial fibrillation, angina 9
• Patient has bone loss concerns (postmenopausal women are particularly vulnerable) 5

Practical Management Recommendations

If the Patient Is Symptomatic

1. First, optimize levothyroxine alone: Increase to 150 mcg and recheck in 6-8 weeks 5
2. Consider reducing liothyronine: The 50 mcg dose is high; try 25 mcg or discontinue entirely
3. Rule out other causes: Depression, anemia, sleep apnea, vitamin D deficiency often masquerade as hypothyroid symptoms

If the Patient Feels Well

Do not chase the free T4 number 2. The combination of:

• TSH 0.570 (normal range)
• Free T3 3.4 (likely upper-normal)
• No symptoms of over- or under-treatment

...suggests adequate tissue thyroid hormone delivery despite the low free T4.

Common Pitfalls to Avoid

• Don't use TSH alone to guide therapy in patients on liothyronine—it becomes unreliable 5, 1
• Don't assume low free T4 means underdosing—in combination therapy, this is expected 4, 10
• Don't ignore medication interactions—iron, calcium, and PPIs can persist in causing problems even with dose separation 7
• Don't continue liothyronine without clear indication—guidelines recommend levothyroxine monotherapy for most patients 5, 6

The 50 mcg liothyronine dose is driving the biochemical pattern you're seeing. If there's no compelling reason for combination therapy (most patients don't benefit 6), consider transitioning to levothyroxine monotherapy at approximately 200-225 mcg daily and reassessing in 6-8 weeks.